Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | GSK3B | P49841 | 14/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14427460 | 1.00 | CDK2 (1.00) | CDK2GSK3BCDK1CHEK1CCNE1 | |
| SCHEMBL5001033 | 1.00 | CDK2 (1.00) | CDK2GSK3BCDK1CHEK1CCNE1 | |
| SCHEMBL14427497 | 0.95 | CDK2 (0.91) | CDK2GSK3BCDK1CHEK1CCNE1 | |
| SCHEMBL14427509 | 0.91 | CDK2 (0.85) | CDK2GSK3BCDK1CHEK1 | |
| SCHEMBL14427438 | 0.91 | CDK2 (0.84) | CDK2GSK3BCDK1CHEK1 | |
| SCHEMBL14427397 | 0.91 | CDK2 (0.84) | CDK2GSK3BCDK1CHEK1CCNE1 | |
| SCHEMBL14427474 | 0.91 | CDK2 (0.83) | CDK2GSK3BCDK1CHEK1 | |
| SCHEMBL14427482 | 0.90 | CDK2 (0.82) | CDK2GSK3BCDK1CHEK1CCNE1 | |
| SCHEMBL14427436 | 0.90 | CDK2 (0.82) | CDK2GSK3BCDK1CHEK1CCNE1 | |
| SCHEMBL14427440 | 0.90 | CDK2 (1.00) | CDK2GSK3BCDK1CHEK1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8067424-B2 | Selective inhibitors for cyclin-dependent kinases | EMORY UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067424-B2 | Selective inhibitors for cyclin-dependent kinases | EMORY UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100261683-A1 | Selective Inhibitors for Cyclin-Dependent Kinases | EMORY UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261683-A1 | Selective Inhibitors for Cyclin-Dependent Kinases | EMORY UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261683-A1 | Selective Inhibitors for Cyclin-Dependent Kinases | CDK7, CCNK, CDK17 | CDK2 5/4885GSK3B 380/4885CDK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.